The Phase II study was a randomized, double-blind, and placebo-controlled dose-ranging study to evaluate the efficacy and safety of ABT-894 in approximately 200 adults with attention-deficit hyperactivity disorder (ADHD), and with atomoxetine as active control.
The ABT-894 compound was discovered by a joint scientific team from NeuroSearch and Abbott under collaboration between the two companies.
Results from the Phase II study show that ABT-894 was efficacious in adult ADHD measured as a statistically significant improvement on the primary endpoint, the total score of the Conners’s adult ADHD rating scales. ABT-894 and atomoxetine appeared to be comparable across efficacy measures.
In the study, ABT-894 was safe and generally well tolerated and demonstrated statistically significant efficacy compared to placebo in adults suffering from ADHD.
Flemming Pedersen, CEO in NeuroSearch, said: “We are very pleased by the positive results seen in this Phase II adult ADHD study with ABT-894 and excited about the prospects for this compound as a potential new treatment of ADHD.”